Compare VRAX & DOMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAX | DOMH |
|---|---|---|
| Founded | 2013 | 1967 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 55.0M |
| IPO Year | 2021 | 2010 |
| Metric | VRAX | DOMH |
|---|---|---|
| Price | $0.19 | $2.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 179.0K | 66.2K |
| Earning Date | 03-10-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 22.41% |
| EPS Growth | N/A | ★ 39.75 |
| EPS | N/A | ★ 7.86 |
| Revenue | N/A | ★ $18,146,000.00 |
| Revenue This Year | $217,274.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.37 |
| Revenue Growth | N/A | ★ 789.95 |
| 52 Week Low | $0.18 | $2.85 |
| 52 Week High | $1.35 | $8.40 |
| Indicator | VRAX | DOMH |
|---|---|---|
| Relative Strength Index (RSI) | 38.67 | 35.46 |
| Support Level | N/A | $2.85 |
| Resistance Level | $0.25 | $3.56 |
| Average True Range (ATR) | 0.02 | 0.24 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 13.53 | 6.06 |
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.